Age-dependent changes in fasl (CD95L) modulate macrophage function in a model of age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 8, 2013, Pages 5321-5331

  Zhao, Hui ^a   Roychoudhury, Jayeeta ^a   Doggett, Teresa A ^a   Apte, Rajendra S ^a   Ferguson, Thomas A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agerelated macular degeneration; Cell migration; Cytokine; Immune privilege; Macrophages; Neovascularization

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; DOXYCYCLINE; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; LOW LEVEL LASER THERAPY; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; WESTERN BLOTTING;

EID: 84881493874     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12122     Document Type: Article

References (74)

1. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011;12:173-181.
2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-2617.
3. Zarbin MA. Current concepts in the pathogenesis of agerelated macular degeneration. Arch Ophthalmol. 2004;122: 598-614.
4. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80:595-606.
5. Espinosa-Heidmann DG, Suner I, Hernandez EP, Frazier WD, Csaky KG, Cousins SW. Age as an independent risk factor for severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:1567-1573.
6. Bora NS, Kaliappan S, Jha P, et al. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol. 2007;178:1783-1790.
7. Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 2006;3:e310.
8. Roychoudhury J, Herndon JM, Yin J, Apte RS, Ferguson TA. Targeting immune privilege to prevent pathogenic neovascularization. Invest Ophthalmol Vis Sci. 2010;51:3560-3566.
9. Semkova I, Fauser S, Lappas A, et al. Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization. Faseb J. 2006;20:1689-1691.
10. Tsutsumi C, Sonoda KH, Egashira K, et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol. 2003;74:25-32.
11. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3578- 3585.
12. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
13. Ramkumar HL, Zhang J, Chan CC. Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD). Prog Retin Eye Res. 2010;29:169-190.
14. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/ CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-7232.
15. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3586-3592.
16. Kelly J, Khan AA, Yin J, Ferguson TA, Apte RS. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest. 2007;117:3421-3426.
17. Ferguson TA, Apte RS. Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol. 2008;30: 111-119.
18. Kovacs EJ, Palmer JL, Fortin CF, Fülöp T Jr, Goldstein DR, Linton PJ. Aging and innate immunity in the mouse: impact of intrinsic and extrinsic factors. Trends Immunol. 2009;30:319- 324.
19. Rymkiewicz P, Heng Y, Vasudev A, Larbi A. The immune system in the aging human. Immunol Res. 2012;53:235-250.
20. Stout RD, Suttles J. Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes. Immunol Rev. 2005;205:60-71.
21. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006;213:228- 238.
22. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
23. Ferguson TA, Green DR. Fas-ligand and immune privilege: the eyes have it. Cell Death Differ. 2001;8:771-772.
24. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
25. Stuart PM, Pan F, Plambeck S, Ferguson TA. FasL-Fas interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci. 2003;44:93-98.
26. Barreiro R, Schadlu R, Herndon J, Kaplan HJ, Ferguson TA. The role of Fas-FasL in the development and treatment of ischemic retinopathy. Invest Ophthalmol Vis Sci. 2003;44:1282-1286.
27. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med. 1999;5:292-297.
28. Bajou K, Peng H, Laug WE, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell. 2008;14:324-334.
29. Yap R, Veliceasa D, Emmenegger U, et al. Metronomic lowdose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res. 2005;11: 6678-6685.
30. Stuart PM, Pan F, Yin X, Haskova Z, Plambeck S, Ferguson TA. Effect of metalloprotease inhibitors on corneal allograft survival. Invest Ophthalmol Vis Sci. 2004;45:1169-1173.
31. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA. CD95 induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
32. Brown NJ, Hutcheson J, Bickel E, et al. Fas death receptor signaling represses monocyte numbers and macrophage activation in vivo. J Immunol. 2004;173:7584-7593.
33. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, Garner HR. Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther. 2008;324:1196-1203.
34. Fainaru O, Adini I, Benny O, et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. Faseb J. 2008;22:3728- 3735.
35. Rossiter HB, Scadeng M, Tang K, Wagner PD, Breen EC. Doxycycline treatment prevents alveolar destruction in VEGFdeficient mouse lung. J Cell Biochem. 2008;104:525-535.
36. Hebda PA, Whaley D, Kim HG, Wells A. Absence of inhibition of cutaneous wound healing in mice by oral doxycycline. Wound Repair Regen. 2003;11:373-379.
37. Verreck FAW, de Boer T, Langenberg DML et al. Human IL-23 producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 2004;101:4560-4565.
38. Sierra-Filardi E, Vega MA, Sánchez-Mateos P, Corbí AL, Puig Kröger A. Heme oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology. 2010;215:788-795.
39. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys. 2002;408:155-161.
40. Chau KY, Sivaprasad S, Patel N, Donaldson TA, Luthert PJ, Chong NV. Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. Eye (Lond). 2007;21:1511-1515.
41. Hussain AA, Lee Y, Zhang JJ, Marshall J. Disturbed matrix metalloproteinase activity of Bruch's membrane in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52: 4459-4466.
42. Lambert V, Wielockx B, Munaut C, et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. Faseb J. 2003;17:2290-2292.
43. Tatar O, Adam A, Shinoda K, et al. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy. Br J Ophthalmol. 2007;91: 1183-1189.
44. Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. Cell. 2007;129:447-450.
45. Nagata S, Golstein P. The Fas death factor. Science. 1995;267: 1449-1456.
46. Gregory MS, Hackett CG, Abernathy EF, et al. Opposing roles for membrane bound and soluble fas ligand in glaucomaassociated retinal ganglion cell death. PLoS One. 2011;6: e17659.
47. Letellier E, Kumar S, Sancho-Martinez I, et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity. 2010;32: 240-252.
48. Seino KI, Iwabuchi K, Kayagaki N. et al. Cutting edge: chemotactic activity of soluble Fas ligand against phagocytes. J Immunol. 1998;161:4484-4488.
49. Raoul W, Auvynet C, Camelo S, et al. CCL2/CCR2 and CX3CL1/ CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation. 2010;7:87.
50. Yamada K, Sakurai E, Itaya M, Yamasaki S, Ogura Y. Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice. Invest Ophthalmol Vis Sci. 2007;48:1839- 1843.
51. O'Reilly LA, Tai L, Lee L, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 2009;461: 659-663.
52. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res. 2009;28:348-368.
53. Bok D. Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci USA. 2005;102:7053-7054.
54. Muther PS, Semkova I, Schmidt K, et al. Conditions of retinal glial and inflammatory cell activation after irradiation in a GFPchimeric mouse model. Invest Ophthalmol Vis Sci. 2010;51: 4831-4839.
55. Caicedo A, Espinosa-Heidmann DG, Piña Y, Hernandez EP, Cousins SW. Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. Exp Eye Res. 2005;81:38-47.
56. Schulte M, Reiss K, Lettau M, et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007;14: 1040-1049.
57. Zuccato E, Blott EJ, Holt O, et al. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J Cell Sci. 2007;120:191-199.
58. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180-192.
59. Hsu HC, Scott DK, Mountz JD. Impaired apoptosis and immune senescence - cause or effect? Immunol Rev. 2005; 205:130-146.
60. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005;23:344-346.
61. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35.
62. McMenamin PG. Dendritic cells and macrophages in the uveal tract of the normal mouse eye. Br J Ophthalmol. 1999;83: 598-604.
63. Niederkorn JY, Peeler JS, Mellon J. Phagocytosis of particulate antigens by corneal epithelial cells stimulates interleukin-1 secretion and migration of Langerhans cells into the central cornea. Reg Immunol. 1989;2:83-90.
64. Forrester JV, Xu H, Kuffova L, Dick AD, McMenamin PG. Dendritic cell physiology and function in the eye. Immunol Rev. 2010;234:282-304.
65. Lecomte J, Louis K, Detry B, et al. Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization. Cell Mol Life Sci. 2011;68:677- 686.
66. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75:26-39.
67. Cao X, Shen D, Patel MM, et al. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol Int. 2011;61:528-535.
68. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185- 194.
69. Sica A, Schioppa T, Mantovani A, Allavena P. Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717-727.
70. Xie P, Kamei M, Suzuki M, et al. Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344. PLoS One. 2011;6:e28933.
71. Naumnik W, Izycki T, Ossolinska M, Chyczewska E. Serum levels of sFas and sFasL during chemotherapy of lung cancer. Exp Oncol. 2007;29:132-136.
72. Hashimoto H, Tanaka M, Suda T, et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1998;41:657-662.
73. Owonikoko TK, Hossain MS, Bhimani C, et al. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer. 2013;119:1503-1511.
74. Jiang S, Moriarty-Craige SE, Li C, et al. Associations of plasmasoluble fas ligand with aging and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:1345-1349.